期刊文献+

Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris 被引量:4

Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris
原文传递
导出
摘要 Background Dengue is currently a significant global health problem but no vaccines are available against the four dengue serotypes virus infections. The development of safe and effective vaccines has been hampered by the requirement of conferring complete protection against all four dengue serotypes and the lack of a convenient animal model. Virus-like particles (VLPs) have emerged as a promising subunit vaccine candidate. One strategy of vaccine development is to produce a tetravalent dengue subunit vaccine by mixing recombinant VLPs, corresponding to all four dengue virus serotypes. Towards this end, this study aimed to establish a Pichia pastoris (P. pastoris) expression system for production of dengue virus type 1 (DENV-1) VLPs and evaluate the humoral and cellular immune response of this particle in mice. Methods A recombinant yeast P. pastoris clone containing prM and E genes of DENV-1 was constructed and DENV-1 VLPs expressed by this clone were analyzed by sucrose density gradient centrifugation, Western blotting, and transmission electron microscope. Groups of mice were immunized by these particles plus adjuvant formulations, then mice were tested by ELISA and neutralization assay for humoral immune response, and by lymphocyte proliferation and cytokine production assays for a cellular immune response. Results Our data demonstrated that recombinant DENV-1 VLPs consisting of prM and E protein were successfully expressed in the yeast P. pastoris. Sera of VLPs immunized mice were shown to contain a high-titer of antibodies and the neutralization assay suggested that those antibodies neutralized virus infection in vitro. Data from the T lymphocyte proliferation assay showed proliferation of T cell, and ELISA found elevated secretion levels of interferon IFN-γ and IL-4. Conclusions P. pastoris-expressed DENV-1 VLPs can induce virus neutralizing antibodies and T cell responses in immunized mice. Using P. pastoris to produce VLPs offers a promising and economic strategy for dengue virus vaccine development. Background Dengue is currently a significant global health problem but no vaccines are available against the four dengue serotypes virus infections. The development of safe and effective vaccines has been hampered by the requirement of conferring complete protection against all four dengue serotypes and the lack of a convenient animal model. Virus-like particles (VLPs) have emerged as a promising subunit vaccine candidate. One strategy of vaccine development is to produce a tetravalent dengue subunit vaccine by mixing recombinant VLPs, corresponding to all four dengue virus serotypes. Towards this end, this study aimed to establish a Pichia pastoris (P. pastoris) expression system for production of dengue virus type 1 (DENV-1) VLPs and evaluate the humoral and cellular immune response of this particle in mice. Methods A recombinant yeast P. pastoris clone containing prM and E genes of DENV-1 was constructed and DENV-1 VLPs expressed by this clone were analyzed by sucrose density gradient centrifugation, Western blotting, and transmission electron microscope. Groups of mice were immunized by these particles plus adjuvant formulations, then mice were tested by ELISA and neutralization assay for humoral immune response, and by lymphocyte proliferation and cytokine production assays for a cellular immune response. Results Our data demonstrated that recombinant DENV-1 VLPs consisting of prM and E protein were successfully expressed in the yeast P. pastoris. Sera of VLPs immunized mice were shown to contain a high-titer of antibodies and the neutralization assay suggested that those antibodies neutralized virus infection in vitro. Data from the T lymphocyte proliferation assay showed proliferation of T cell, and ELISA found elevated secretion levels of interferon IFN-γ and IL-4. Conclusions P. pastoris-expressed DENV-1 VLPs can induce virus neutralizing antibodies and T cell responses in immunized mice. Using P. pastoris to produce VLPs offers a promising and economic strategy for dengue virus vaccine development.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2012年第11期1986-1992,共7页 中华医学杂志(英文版)
基金 This work was supported by grants from the National Science Foundation (No. U0632002) and National High Technology Research Development Program of China (No. 2006AA02A223).
关键词 dengue virus virus-like particles Pichia pastoris dengue virus, virus-like particles, Pichia pastoris
  • 相关文献

参考文献1

二级参考文献21

  • 1张复春,陈燕清,卢业成,王建,陈万山,洪文欣.广州市2002-2003年1032例登革热患者流行病学特征分析[J].中华流行病学杂志,2005,26(6):421-423. 被引量:28
  • 2何丽娟,吴新伟,狄飚,蒋力云,杨卫路,鲁恩洁,熊远,周端华.2000-2004年广州市登革热血清学和病原学分析[J].预防医学情报杂志,2006,22(2):150-152. 被引量:22
  • 3方丹云,周经姣,黄骥斌,韩艳平,江丽芳.登革病毒流行株的分离鉴定及其毒力位点变异研究[J].生物技术,2006,16(2):26-27. 被引量:6
  • 4严菊英,卢亦愚,翁景清,茅海燕,冯燕,史雯,徐昌平,李婵,谢荣辉.浙江省登革热暴发疫情的病原学和分子生物学研究[J].病毒学报,2006,22(5):339-344. 被引量:22
  • 5Laneiotti RS, Calisher CH, Gubler DJ, et al. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. Clin Microbiol, 1992, 30 ( 3 ) : 545-551.
  • 6Barrero PR, Mistehenko AS. Complete genome sequencing of dengue virus type 1 isolated in Buenos Aires, Argentina. Virus Res, 2004, 101(2): 135-145.
  • 7Purl B, Neison WM, Henchal EA, et al. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. J Gen Virol, 1997, 78(Pt 9) : 2287-2291.
  • 8Leitmeyer KC, Vanghn DW, Watts DW, et al. Dengue virus structural differences that correlate with pathogenesis. J Virol, 1999, 73(6) : 4738-4747.
  • 9Singh UB, Maitra A, Broor S, et al. Partial nueleotide sequencing and molecular evolution of epidemic causing dengue 2 strains. J Infect Dis, 1999, 180(4) : 959-965.
  • 10Chen Y, Maguire T, Hileman RE, et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med, 1997, 3(8) : 866-871.

共引文献2

同被引文献2

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部